IGF-I stimulation of cell proliferation and c-Fos expression in skeletal muscle cells is markedly enhanced by dexamethasone. The effect of dexamethasone is not mediated by changes in IGF-binding proteins, as evidenced by similar effects of dexamethasone on the actions of insulin, PDGF-BB, and the IGF-I analogue long R3IGF-I. Dexamethasone also does not alter autocrine IGF-II secretion by muscle cells. To investigate the mechanism of the augmentation of IGF-I action, the effects of dexamethasone on intracellular IGF-I signaling pathways were determined. In dexamethasone-treated cells, the levels of IGF-I receptor tyrosine phosphorylation and receptor-associated phosphatidylinositol 3-kinase activity were increased. Dexamethasone-treated cells also showed increased and prolonged tyrosine phosphorylation of the Shc proteins. In contrast, dexamethasone decreased both tyrosine phosphorylation and expression of insulin receptor substrate 1 (IRS-1) and IRS-1-associated phosphatidylinositol 3-kinase activity. Thus, distinct signaling pathways activated by the IGF-I receptor in skeletal muscle cells are differentially regulated by dexamethasone. Potentiation of IGF-I action correlates with increased IGF-I receptor-associated phosphatidylinositol 3-kinase activity and tyrosine phosphorylation of Shc, but appears to be independent of activation of the IRS-1/phosphatidylinositol 3-kinase signaling pathway. (J.
Introduction
IGF-I is a polypeptide hormone with a broad range of metabolic actions that include potent stimulation of cell growth and differentiation in multiple cell types (1) . In human fibroblasts as well as in other cells, the growth-stimulatory effects of IGF-I have reportedly been markedly enhanced by glucocorticoids (2-4).
Glucocorticoids have also been shown to enhance cell proliferation induced by other growth factors, including insulin, EGF, fibroblast growth factor, and PDGF, all of which act via cell surface receptors containing a ligand-activated tyrosine kinase (2, 3, (5) (6) (7) . The mechanism by which glucocorticoids enhance the action of IGF-I and other growth factors has not been elucidated. The objective of this study was to investigate the effects of the glucocorticoid dexamethasone on mitogenic responses to IGF-I in cultured skeletal muscle cells and to define the mechanism of glucocorticoid-induced augmentation of IGF-I action.
The biologic effects of IGF-I are mediated by specific cellsurface receptors (8) (9) (10) . IGF-I binding to the extracellular a subunits activates the tyrosine kinase intrinsic to the cytoplasmic portion of the IGF-I receptor, leading to autophosphorylation of specific tyrosine residues in the receptor /3 subunit (1 1, 12) . One early molecular event that may link the receptor kinase to the biologic actions of IGF-I is tyrosine phosphorylation of insulin receptor substrate-i (IRS-1) .' IRS-1 is a 135-kD cytoplasmic protein that migrates anomalously as a 175-185 kD tyrosine phosphoprotein on SDS-polyacrylamide gels (13) (14) (15) . IRS-1 undergoes tyrosine phosphorylation in response to insulin and IGF-I stimulation of intact cells (16, 17) and represents a direct substrate for the activated insulin and IGF-I receptor kinases (18) . Current evidence suggests that IRS-I acts as a multisite "docking" protein by binding to downstream signal-transducing molecules. Phosphorylation of multiple tyrosine residues found in distinct IRS-1 amino acid motifs results in the association of IRS-I with the src homology 2 (SH2) domains of other cytoplasmic signaling proteins, including phosphatidylinositol (PI) 3-kinase, Syp, GRB-2, and Nck (reviewed in reference 19) . Two specific YMXM motifs mediate IRS-1 association with the 85-kD regulatory subunit of PI 3-kinase, leading to activation of the catalytic subunit of this enzyme (20, 21) . Activated PI 3-kinase is then capable of phosphorylating the D-3 position of various phosphatidylinositols, forming PI(3)P, PI(3,4)P2, and PI(3,4,5)P3, which are believed to regulate certain aspects of cellular growth and metabolism (22) . The IGF-I receptor kinase directly phosphorylates YMXM tyrosine residues in the IRS-1 protein and thus increases the amount of PI 3-kinase activity bound to IRS-1 (18, 23) Pelicci et al. (24) identified a novel gene, Shc, which encodes three protein species of 46, 52, and 66 kD, respectively, termed p46she p52sc, and p66shc. Two of the Shc proteins, p46seh and p52sch, result from the presence of two translationinitiation sites on the same mRNA, whereas p66 h is likely to 1 . Abbreviations used in this paper: aIGF-I R, anti-IGF-I receptor; aIRS-1, anti-IRS-i; DCBS, donor calf bovine serum; IRS-1, insulin receptor substrate-1; PI, phosphatidylinositol; aPY, anti-phosphotyrosine; SH2, src homology 2. result from a distinct transcript (24) . Evidence that the Shc proteins participate in insulin signaling has come from recent studies showing that all three protein species are rapidly phosphorylated in response to insulin stimulation in fibroblasts expressing elevated levels of human insulin receptors (25) (26) (27) ). Tyrosine phosphorylated Shc can then activate cellular signaling by binding the SH2 domain of the GRB-2 protein (25) . GRB-2 forms a stable complex with Sosi, a guanine nucleotide releasing factor for p21 ' (28) , and subsequent activation of p21 leads to the consecutive stimulation of Raf 1 kinase, MEK, and MAP kinase (reviewed in reference 29) . Recent studies in NIH 3T3 cells overexpressing an Shc cDNA have demonstrated that the Shc proteins are also tyrosine phosphorylated in response to IGF-I and may be direct substrates for both the IGF-I and insulin receptor kinases (30) . At present, Shc and IRS-1 represent the only known intracellular tyrosine phosphoproteins that are stimulated by IGF-I in mammalian cells and act as coupling molecules for specific downstream signaling pathways.
In this study, the effects of dexamethasone on IGF-I-induced mitogenesis were investigated in cultured skeletal muscle cells, because skeletal muscle represents an important site of action for the IGFs. Specific high-affinity IGF-I receptors are known to be expressed in skeletal muscle (31) , and both IGF-I and IGF-II peptides are capable of stimulating muscle growth and differentiation (31, 32) . In addition to IGF-I receptors, the presence of mRNA and peptide for both IGF-I and IGF-II has been documented in cloned muscle cell lines and normal fetal and adult muscle tissues (33) , suggesting that a significant component of IGF-I action in muscle cells may be mediated through autocrine as well as paracrine mechanisms. Muscle cells also secrete IGF binding proteins, which may modify the biologic activity of the IGFs (34) . The L6 skeletal muscle cells used in this study express abundant IGF-I receptors (31) and are markedly responsive to the mitogenic actions of IGF-I (31, 35) . In addition, L6 cells express receptors for insulin and PDGF (31, 36) , which makes it possible to study responses to multiple tyrosine kinase-associated growth factors.
To identify glucocorticoid-regulated steps that may explain the increased proliferative effects of IGF-I, we have investigated both extracellular and intracellular components of the mechanism of action of this growth factor. Here we report that dexamethasone markedly potentiates the mitogenic actions of IGF-I on L6 skeletal muscle cells and that this response is associated with increased activity of specific intracellular IGF-I signaling pathways.
Methods
Reagents. Culture medium and donor calf bovine serum were obtained from GIBCO BRL (Grand Island, NY). Recombinant Polyclonal anti-phosphotyrosine (aPY) antibody was prepared in rabbits by injection of phosphotyrosine polymerized by l-ethyl-3(3-dimethyl-aminopropyl)carbodiimide with alanine, threonine, and keyhole limpet hemocyanin (KLH) as previously described (37) . Nonimmunoglobulin proteins were extracted with 6% octanoic acid precipitation, and aPY antibody was then purified by affinity chromatography on a phosphotyramine-sepharose column. Polyclonal anti-peptide antibodies were generated against two peptide sequences corresponding to regions of the IGF-I receptor (aIGF-I R) and IRS-1 (aIRS-1). These included the synthetic peptide ala-ser-phe-asp-glu-arg-gln-pro-tyr-alahis, which contains the COOH-terminal amino acid sequence between residues 1308 and 1318 of the /3 subunit of the human IGF-I receptor reported by Ullrich et al. (9) , and the peptide tyr-ala-ser-ile-asn-phegln-lys-gln-pro-glu-asp-arg-gln, corresponding to the last 14 amino acids in the COOH-terminal region of rat IRS-1 (15). These antibodies were prepared and purified on specific peptide affinity columns as previously described (38) Immunoprecipitation was carried out by incubation of the cell lysate overnight at 4°C with aIGF-I R or aIRS-I antibodies, as indicated.
Immunocomplexes were adsorbed with protein A-sepharose beads for 2 h at 4°C, and the pelleted beads were washed successively in PBS containing 1% NP-40 and 100 mM sodium orthovanadate (three times), 100 mM Tris-HCl (pH 7.6) containing 500 mM LiCl and 100 mM sodium orthovanadate (three times), and 10 mM Tris-HCl (pH 7.6) containing 100 mM NaCl, 1 mM EDTA, and 100 mM sodium orthovanadate (twice). For determination of PI 3-kinase activity in the immunoprecipitate, the sepharose beads were resuspended in 50 ml 10 mM TrisHCl (pH 7.6) containing 100 mM NaCl, 1 mM EDTA, and 100 mM sodium orthovanadate, and then combined with 10 ml 100 mM MgCl2 and 10 ml 2 mg/ml phosphatidylinositol (Avanti Polar Lipids, Alabaster, AL) sonicated in 10 mM Tris-HCl (pH 7.6) containing 1 mM EGTA. The PI 3-kinase reaction was started by the addition of 10 ml 10 mM ATP containing 30 mCi [y_32p] ATP. After 10 min at 22°C with constant vortexing, the reaction was stopped by the addition of 20 ml 8 N HCl and 160 ml chloroform/methanol (1:1, vol/vol). The samples were centrifuged, and the lower organic phase was removed and applied to a silica gel TLC plate precoated with 1% potassium oxalate (Merck, Darmstadt, Germany). The plates were developed in chloroform/methanol/water/ammonia (60:47:11.3:2, vol/vol), dried, and visualized by autoradiography. The PI-3 product was identified by its comigration with a PI-4 standard and quantitated by scanning densitometry (Molecular Dynamics).
Immunoblotting. For identification and quantitation of specific proteins by immunoblotting, cell lysates were prepared and immunoprecipi- These results are similar to the reported effects of glucocorticoids on IGF-I-stimulated DNA synthesis in human fibroblasts (2, 3).
To assess whether treatment with dexamethasone and/or IGF-I altered the state of differentiation of L6 myoblasts, the amount of myosin heavy chain in the cell lysates was measured by immunoblotting with anti-myosin heavy chain antibodies. The induction of myosin heavy chain expression has been used as a marker of L6 cell differentiation because this protein increases severalfold when myoblasts fully differentiate into myotubes (44) . In cells treated with dexamethasone for 72 h, myosin heavy chain content was decreased to 45 .6+1.1% of control cells, P < 0.05. By contrast, IGF-I treatment for 16 h induced only a modest 20% decrease in myosin heavy chain content in control cells and had no effects on myosin heavy chain content in dexamethasone-treated cells. These results indicate that L6 myoblasts treated with dexamethasone were moderately less differentiated compared with control myoblasts.
c -Fos and c-Jun expression. The stimulation of proto-oncogene expression by a number of growth factors has been implicated as an intermediary event involved in the regulation of cell growth and proliferation. To investigate whether the effects of dexamethasone in potentiating IGF-I-stimulated cell proliferation were associated with a change in IGF-I stimulation of proto-oncogene expression, c-Fos and c-Jun steady-state mRNA levels were studied in undifferentiated L6 cells by Northern analysis. As shown in Dexamethasone effects on IGF-II production and responses to other growth factors. Because the autocrine production of IGFs and IGF binding proteins may have important effects on muscle cell proliferation and/or differentiation, we considered the possibility that dexamethasone could augment IGF-I-stimulated mitogenesis in L6 cells via changes in the production of IGF-II and/or IGF binding proteins. To investigate the effect of dexamethasone on IGF-II production by L6 cells, monolayers were incubated in the presence or absence of dexamethasone (1 AiM) for various times, and IGF-II concentration in the medium was determined by radioimmunoassay (Fig. 3) . As previously reported by other investigators (45), IGF-II was produced by L6 cells and its concentration in the culture medium progressively increased during the 68 h of study. Treatment with dexamethasone did not alter IGF-II concentration in the culture medium at any time point. IGF-I was also measured in the culture medium under the same experimental conditions using a specific radioimmunoassay and found to be consistently below the detection limit of the assay (data not shown). These results rule out the possibility that the augmentation of IGF-I responsiveness by dexamethasone could occur through increased synthesis of IGF-II or IGF-I.
To determine whether dexamethasone increased IGF-Istimulated cell growth by changing the levels or activities of IGF binding proteins, the effects of dexamethasone on DNA synthesis stimulated by IGF-I and the analogue longR3IGF-I were compared. LongR3IGF-I binds to the IGF-I receptor and stimulates biologic responses but has a very low affinity for IGF binding proteins (46) . As shown in Fig. 4 , dexamethasone increased the effects of IGF-I and longR3IGF-I on L6 myoblast DNA synthesis to a similar extent. Dexamethasone also increased the stimulation of DNA synthesis by insulin and the BB form of platelet-derived growth factor (PDGF-BB) ( Fig.   1476 Giorgino et al. Fig. 6 (left) . The total amount of basal and stimulated IGF-I receptor tyrosine phosphorylation was increased modestly but significantly in dexamethasone-treated cells. IGF-I receptor content determined by immunoblotting with aIGF-I R antibody was increased in dexamethasone-treated cells by 70% (Fig.   6, right) .
To determine the effects of dexamethasone on the cellular content of insulin and PDGF P receptors, total cell lysates from control and dexamethasone-treated L6 myoblasts were subjected to immunoprecipitation and immunoblotting with aIns The effects of dexamethasone on IGF-I stimulation of IRS-1 tyrosine phosphorylation are shown in Fig. 7 (left) . Maximal IRS-1 tyrosine phosphorylation was significantly decreased in dexamethasone-treated compared with control cells 10 (Fig. 8) . Autocrine secretion of IGF-H from L6 myoblasts may account, at least in part, for the observed amount of basal receptor-associated PI 3-kinase activity. In the basal state, dexamethasone-treated cells had a similar amount of PI 3-kinase activity associated with IGF-I receptors in comparison with control cells. However, the amount of IGF-I-stimulated PI 3-kinase activity that co-immunoprecipitated with IGF-I receptors was increased in dexamethasone-treated cells compared with control cells.
The amount of PI 3-kinase activity present in aIRS-i immunoprecipitates was several-fold greater than in aIGF-I R immunoprecipitates, which is in agreement with previously reported studies (47) . In control cells, IGF-I stimulation induced a rapid and marked (42- activity associated with IRS-1 (Fig. 9) . In cells treated with 1 ,qM dexamethasone for 72 h, there was no difference in the basal level of PI 3-kinase activity associated with IRS-1, but IGF-1 stimulation induced only a 23-fold increase in IRS-1-associated PI 3-kinase activity. Thus, in comparison with control cells, dexamethasone reduced by 45% the levels of IGF-Istimulated PI 3-kinase activity associated with IRS-1. The observed findings of decreased IRS-i -associated PI 3-kinase activity and increased IGF-I receptor-associated PI 3-kinase activity correlate with the decrease in both the expression and tyrosine phosphorylation of IRS-1 and with the increase in the expression and tyrosine phosphorylation of IGF-I receptors, respectively. Because IRS-1 tyrosine phosphorylation and IRSl-associated PI 3-kinase activity are decreased by dexamethasone under conditions where IGF-I-stimulated mitogenesis is augmented, the IRS-1/PI 3-kinase pathway is unlikely to be involved in the potentiation of IGF-I action by glucocorticoids.
Shc tyrosine phosphorylation. The decrease in IRS-I phosphorylation and associated PI 3-kinase activity together with the increase in IGF-I receptor tyrosine phosphorylation suggest that the effects of dexamethasone on IGF-I-stimulated mitogenesis could be mediated by signaling events initiated by the IGF-I receptor but distinct from IRS-1 signaling pathways. The three Shc proteins (46, 52, and 66 kD), which are rapidly tyrosine phosphorylated in response to insulin and growth factor stimulation of intact cells (25) (26) (27) , represent an alternative intracellular pathway that could be involved in glucocorticoid action. Tyrosine phosphorylation of proteins in this molecular weight range in total cell lysates of IGF-I-stimulated L6 myoblasts may not have been observed by immunoblotting with aPY antibody (see Fig. 5 ) because of the limited sensitivity of this technique.
To investigate tyrosine phosphorylation of the Shc proteins, L6 myoblasts were treated with 100 nM IGF-I for various times, and cell lysates were subjected to immunoprecipitation with polyclonal Shc antibody and subsequent immunoblotting with phosphotyrosine antibody. As shown in Fig. 10 (left) , IGF-I markedly stimulated tyrosine phosphorylation of p52ShC and, to a lesser extent, of p66ShC and p46"S1. Tyrosine phosphorylation for 72 h and then stimulated with 100 nM human recombinant IGF-I for the indicated times. Total cell lysates were subjected to immunoprecipitation with Shc antibody, and the resulting immunoprecipitates were resolved by SDS-PAGE on 10% acrylamide gels, transferred to nitrocellulose, and blotted with the aPY antibody and "NI-labeled protein A, as described in Methods.
slowly decreased after 90 min. A similar time course of tyrosine phosphorylation of the Shc proteins has been observed in 3T3 NIH fibroblasts overexpressing insulin receptors (26) . When cells were treated with dexamethasone for 72 h, the level of IGF-I-stimulated tyrosine phosphorylation of all three Shc proteins was significantly higher than control cells. This difference was evident after 5 min of stimulation with 100 nM IGF-I and became more pronounced at later time points (Fig. 10, right) . Quantitation of multiple experiments (Fig. 11, left) indicated that in control cells, IGF-I stimulation for 5 min increased the levels of tyrosine phosphorylation of p46sc, p52sc, and p66shc by 1.7-fold, 6-fold, and threefold, respectively. These effects were augmented by approximately 80% in cells treated with dexamethasone, and there was also an increased level of basal tyrosine phosphorylation of all three Shc proteins in dexamethasone-treated cells. In addition, while tyrosine phosphorylation of p52slK and p66"hc decreased significantly in control cells after 90 min of stimulation with IGF-I, a similar decrease was not observed in cells treated with dexamethasone in which tyrosine phosphorylation of p52shc and p66sbc persisted at high levels ( Fig. 11, left) . Although dexamethasone induced a modest increase in protein content of all Shc proteins (by 15-25%; Fig. 11 , right), this did not account for the increase in Shc tyrosine phosphorylation. The effect of dexamethasone on Shc tyrosine phosphorylation correlates with and may be mechanistically related to the increase in IGF-I-stimulated mitogenesis induced by dexamethasone.
Discussion
Glucocorticoids have been shown to potentiate the mitogenic actions of IGF-I in multiple cultured cell types (2) (3) (4) , but the mechanism of this response is unknown. In the present study, the glucocorticoid dexamethasone was shown to augment the stimulatory effects of IGF-I on DNA synthesis and expression of the c-Fos proto-oncogene in undifferentiated L6 skeletal muscle cells. The mechanism of these effects of dexamethasone was investigated by examining elements of the IGF-I signaling pathway. IGFs and IGF binding proteins secreted by muscle cells have important roles in the control of muscle cell growth and differentiation. Autocrine IGF-II secretion appears to be a major determinant of the differentiation of cultured muscle cells from myoblasts to myotubes in low-serum medium (45) . In addition, increasing IGF-ll secretion into the culture medium by muscle cells during differentiation induces a 60% decrease in the expression of IGF-I receptors (48) . Although dexamethasone thus could influence the degree of muscle cell differentiation and the responsiveness of muscle cells to IGF-I by inducing changes in IGF-H synthesis, IGF-H levels in the medium were unaffected by dexamethasone in this study. IGF-I receptor expression is increased by dexamethasone in skeletal muscle cells (49) , but this appears to be independent of changes in IGF-ll.
Glucocorticoids have been reported to regulate the levels of IGF binding proteins in experimental animals and human subjects. For example, dexamethasone stimulates transcription of the IGFBP-1 gene and synthesis of the IGFBP-1 protein in rat hepatoma cells (50) . Although dexamethasone may also affect IGF binding protein synthesis in L6 cells, changes in binding proteins cannot explain the effects of dexamethasone on DNA synthesis and cell proliferation. When human recombinant IGF-I and the analogue longR3IGF-I were compared, a similar augmentation of hormone action by dexamethasone was observed, even though longR3IGF-I has a much lower affinity for binding proteins. Dexamethasone also increased the growth stimulatory effects of insulin and PDGF-BB, two other hormones that do not interact with IGF binding proteins.
Having demonstrated that the effects of dexamethasone on the responsiveness to IGF-I in L6 myoblasts involve steps proximal to the induction of the proto-oncogene c-Fos and distal to the interaction of IGF-I with binding proteins, we investigated the initial steps in intracellular signaling by IGF-I. Treatment of L6 myoblasts with dexamethasone significantly increased the level of tyrosine phosphorylation and total cell content of IGF-I receptors. The increased level of tyrosine phosphorylation likely reflects an increased number of cell surface receptors that bind and are activated by IGF-I. Similar to these findings, dexamethasone has been shown to enhance IGF-I binding in porcine granulosa cells by increasing the number of cell surface receptors (4) . The increased level of receptor tyrosine phosphorylation in dexamethasone-treated cells raises the possibility that higher tyrosine kinase activity at the cell surface could result in increased tyrosine phosphorylation of IGF-I receptor substrates. In contrast with the increased tyrosine phosphorylation and content of IGF-I receptors, however, dexamethasone decreased tyrosine phosphorylation and content of the IGF-I receptor substrate IRS-1. Previous studies in 3T3-Ll adipocytes have demonstrated a similar effect of glucocorticoids on the content of IRS-l that appears to be mediated primarily by inhibition of the transcription of IRS-1 mRNA (51) . The oppositely directed effects of dexamethasone on receptor and IRS-1 tyrosine phosphorylation correlate with the levels of expression of these two proteins in L6 myoblasts. In previous studies (38), we have observed discoordinate changes of insulin receptor and IRS-1 tyrosine phosphorylation in the skeletal muscle of glucocorticoid-treated rats compared with controls, indicating that the levels of tyrosine phosphorylation of the receptor and the substrate IRS-I can also be independently regulated in vivo.
Dexamethasone significantly increased IGF-I receptor-associated PI 3-kinase activity, whereas IRS-l-associated PI 3-kinase activity was decreased by the glucocorticoid. The oppositely directed effects of dexamethasone on receptor and IRS-1-associated PI 3-kinase activity are directly correlated with and appear to reflect the levels of expression and tyrosine phosphorylation of these two proteins in L6 cells. In particular, IGF-I receptor expression and tyrosine phosphorylation were increased by 70 and 25%, respectively, and IGF-I receptorassociated PI 3-kinase activity was increased by 40% in dexamethasone-treated L6 myoblasts. PI 3-kinase association with the IGF-I receptor could occur via the formation of IGF-I receptor * IRS-1 * PI 3-kinase ternary complexes, as demonstrated for the insulin receptor (52) . However, PI 3-kinase may also directly associate with the IGF-I receptor through the YAHM motif at the COOH-terminus, which conforms to the required YXXM structure and has been shown to directly bind kinase in the case of the insulin receptor (53) . A direct interaction between partially purified insulin receptors and fusion proteins containing the NH2-or COOH-terminal SH2 domains of PI 3-kinase has been demonstrated in vitro, and a tyrosyl phosphopeptide derived from the insulin receptor COOH-terminus containing the Y 1322THM sequence has been shown to increase PI 3-kinase catalytic activity (53) . Whereas a significant amount of PI 3-kinase activity was found to be associated with the IGF-I receptor in L6 myoblasts, we were unable to detect phosphorylated IRS-1 associated with the IGF-I receptor by phosphotyrosine antibody blotting of aIGF-I R immunoprecipitates (see Fig. 5 ). However, these results do not allow us to conclude that the association of PI 3-kinase with the IGF-I receptor was direct because the amount of receptor-associated IRS-1 may be too small to be detected by standard immunoprecipitation/immunoblotting methods. It has been suggested that PI 3-kinase localization may be relevant to the signaling capability of the enzyme because PI 3-kinase activation appears to involve its redistribution within the cell (54) . Although quantitatively small relative to the entire cellular PI 3-kinase, it is thus possible that a separate pool of IGF-I receptor-associated PI 3-kinase could have important and distinct cellular functions.
Several observations suggest a key if not essential role for IRS-1 in the control of cell proliferation by insulin and IGF-I. Expression of IRS-1 in the hematopoietic 32D cell line, which lacks endogenous IRS-1, allowed these cells to respond to insulin with DNA synthesis (55) . By contrast, inhibition of IRS-1 expression by an antisense IRS-1 RNA resulted in a 30-50% decrease in insulin-stimulated IRS-1 tyrosine phosphorylation and in a coordinate decrease in IRS-i-associated PI 3-kinase activity in CHO cells (56). This was associated with a marked inhibition of insulin-stimulated DNA synthesis and decreased transcriptional activation of the c-Fos promoter, indicating that a relatively modest reduction of IRS-1 function is sufficient to cause a substantial impairment of insulin action. In an additional study, microinjection of aIRS-i antibody in Rat-i fibroblasts overexpressing insulin receptors completely inhibited insulin and also IGF-I stimulation of DNA synthesis (57) . In spite of the demonstrated relationship between IRS-1 and hormonestimulated DNA synthesis, however, the decreased levels of expression and tyrosine phosphorylation of IRS-1 and IRS-1-associated PI 3-kinase activity in L6 myoblasts treated with dexamethasone provide strong evidence against the involvement of IRS-1 in the mechanism of the augmented responsiveness to IGF-I. The (24) and therefore represent potential intracellular targets subject to regulation by glucocorticoids. Whereas IRS-1 is not involved in signaling by other growth factors, the Shc proteins appear to represent an important component of mitogenic signaling by multiple tyrosine kinase growth factor receptors, including insulin, IGF-I, EGF, and PDGF (24, 28, 30) .
Treatment of L6 myoblasts with IGF-I resulted in easily detectable stimulation of tyrosine phosphorylation of all three Shc proteins. This response is of particular interest, because L6 myoblasts express a physiologic number of IGF-I receptors that is similar to IGF-I receptor abundance in fetal muscle tissue (31, 58) . It has been shown previously that tyrosine phosphorylation of Shc can be induced by insulin in NIH-3T3 or CHO fibroblasts overexpressing insulin receptors but not in untransfected fibroblasts (25) (26) (27) , and that IGF-I induces Shc tyrosine phosphorylation only in NIH-3T3 fibroblasts overexpressing Shc (30) . In PC-12 pheochromocytoma cells, both EGF and nerve growth factor can stimulate Shc tyrosine phosphorylation, whereas insulin has no detectable effect on this response under conditions where insulin-stimulated tyrosine phosphorylation of insulin receptors and IRS-I and activation of PI 3-kinase in IRS-I immunoprecipitates occur (59) . Taken together, these results suggest that IGF-I stimulation of the Shc pathway may be cell context specific and thus play a physiologically relevant role in L6 myoblasts. In dexamethasone-treated L6 cells, IGF-I stimulation of tyrosine phosphorylation of all three Shc proteins was increased. The level of Shc tyrosine phosphorylation was elevated at early time points and remained increased for at least 90 min after IGF-I stimulation.
Several observations suggest that tyrosine phosphorylation of the Shc proteins may be involved in the control of cell proliferation and/or transformation. In cells transformed by the oncogenic tyrosine kinases v-src, v-fps, and erbB-2, all three Shc proteins are "constitutively" tyrosine phosphorylated with a relatively high stoichiometry of tyrosine phosphorylation (60, 61) . On the other hand, microinjection of antibodies to the Shc proteins into Ratl fibroblasts overexpressing human insulin receptors inhibits DNA synthesis induced by insulin, IGF-I, and EGF, indicating that Shc is an important component of a mitogenic signal transduction pathway that is shared by these hormones (62) . The increase in the maximal amount of Shc tyrosine phosphorylation and the persistence of the Shc proteins in the phosphorylated state after IGF-I stimulation of L6 myoblasts treated with dexamethasone may thus represent a mechanism leading to the increased mitogenic response. Although it is possible that dexamethasone may increase IGF-I stimulation of DNA synthesis and c-Fos expression by distinct mechanisms, the presence of a higher amount and extent of tyrosine phosphorylation of the Shc proteins may be sufficient to determine all of the increased responsiveness to IGF-I. This conclusion is consistent with the recent observation that cells transfected with a Shc cDNA and expressing increased amounts of the Shc proteins are able to advance into the early phases of the cell cycle and are more sensitive to the growth-promoting effects of insulin (30) . Whether an increased level of Shc tyrosine phosphorylation potentiates IGF-I-stimulated mitogenesis in L6 cells by increased activity of the GRB-2/p2i pathway (25, 28) or other Shc-dependent pathways remains to be determined. The increase in Shc tyrosine phosphorylation observed in L6 myoblasts treated with dexamethasone may also contribute to the reduced state of differentiation of these cells. This possibility is substantiated by the observation that expression of the N-ras oncogene in C2 myoblasts, which results in permanent activation of the p21 pathway, causes inhibition of cell differentiation (63) .
The basis for the increased and prolonged tyrosine phosphorylation of Shc observed in L6 myoblasts treated with dexamethasone is unclear. Although total cell content of the Shc proteins was increased by dexamethasone, the magnitude of this change was modest compared with the increase in tyrosine phosphorylation and does not explain the prolonged state of Shc phosphorylation. The amino acid sequence NPXY has been shown to be a consensus binding site for Shc (64) . Interestingly, NPXY sequences are present in the juxtamembrane region of both the insulin and IGF-I receptors, and the tyrosine residue in these motifs (Tyr-960 and Tyr-950 in the human insulin and IGF-I receptors, respectively) has been shown to be required for interaction with IRS-1 (65) . Under conditions where IRS-1 content is markedly reduced and Shc content significantly increased (as in L6 cells treated with dexamethasone), it is possible that preferential interaction of the IGF-I receptor with Shc could occur and that this could result in greater tyrosine phosphorylation of the Shc proteins. The increase in Shc tyro-sine phosphorylation by -80% directly correlates with the increase in expression and tyrosine phosphorylation of IGF-I receptors (by 70 and 25%, respectively). Therefore, an increased amount of phosphorylated receptors may also contribute to the augmentation of Shc phosphorylation in dexamethasone-treated L6 myoblasts.
Differential regulation of the IRS-1/PI 3-kinase and Shc signaling pathways by dexamethasone appears to affect two noninteracting signaling systems. Although the Shc proteins contain an SH2 domain, a direct interaction between the SH2 domain of the Shc proteins and tyrosine phosphorylated IRS-1 does not appear to occur (25) . Similarly, tyrosine phosphorylated Shc proteins do not interact with the SH2 domains of the p85 subunit of PI 3-kinase, probably because they lack the specific YXXM/YMXM consensus sequences that are required for the association of tyrosine phosphorylated proteins with the SH2 domains of p85 (66) . Thus, PI 3-kinase activity was not detected in anti-Shc immunoprecipitates (61) , and overexpression of Shc proteins in fibroblasts does not modify basal PI 3-kinase activity or activation induced by insulin and IGF-I (30) .
Although it is apparent that both the IRS-1/PI 3-kinase and the Shc signaling pathways may participate in the regulation of cell proliferation in response to insulin and IGF-I, the relative contribution of each pathway to this process has not yet been elucidated. In addition, the role of specific signaling systems in mammalian cells expressing a physiologic number of receptors has not been investigated. The results of our study show, for the first time, that the glucocorticoid dexamethasone, an important regulator of mitogenic responses in multiple cell types, can specifically augment the activity of the Shc signaling pathway by increasing the expression and tyrosine phosphorylation of the Shc proteins. In the same cells, dexamethasone inhibits a second distinct signaling pathway that involves tyrosine phosphorylation of IRS-1 and activation of PI 3-kinase. Further investigation of glucocorticoid regulation of the distinct signaling pathways activated by IGF-I receptors may contribute to our understanding of the physiologic relevance of the multiple intracellular signal transduction systems in skeletal muscle cells and other cell types.
